Fermion, which is part of the Orion Corporation, is a Finnish manufacturer of active pharmaceutical ingredients (APIs) that is most well-known for its highly potent APIs (HPAPIs), which require special expertise. Fermion has over 200 customers globally.


In Hanko, the new production unit 4 was completed in 2018, at which time part of the new factory premises were left empty to await future growth investments. Now, one of the vacant special synthesis facilities will be taken into use which will increase and enhance the manufacturing capacity of Hanko plant. New special synthesis module will have 18m3 reactor capacity with centrifuge and dryer as collection equipment for API’s and intermediates. New module is expected to be ready for operation at the end of 2025.


With this investment Fermion will be able to secure and increase supply to our external customers in growing market demand. This investment also clearly shows Fermion’s commitment to developing the operations of the Hanko API site and the desire to invest in serving our customers.